Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 401–500 of 999
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
“inclusion criterion also did not show robust efficacy (Honig et al., 2018).”
BackgroundDuggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 30
Bell, S., Marco, M. D., Barnes, K., Shaw, P. J., Ferraiuolo, L., Blackburn, D. J., Mortiboys, H., & Venneri, A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020032 · Cited by 31
“Strategies aimed at reducing the amyloid load in the brain, however, have failed to control the disease [6] and have resulted in a large number of clinical trials that have failed to achieve primary outcome measures [7].”
BackgroundYang, X., & Tohda, C. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02052-9 · Cited by 28
“…tests, Designer receptors exclusively activated by designer drugs (DREADDs) experiments, Antero-grade labeling using BDA, Immunohistochemistry, Collagen type I coating and measurement of axonal length, Live cell imaging using triple chamber neuron device, Image analysis, and Statistical analysis.”
MethodAbushakra, S. R., Porsteinsson, A. P., Sabbagh, M., Watson, D., Power, A., Liang, E., MacSweeney, E., Boada, M., Flint, S., McLaine, R., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12498 · Cited by 41
Self-citationAlzheimer’s Disease Research Using Human Microglia
Lue, L., Beach, T. G., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8080838 · Cited by 32
McRae‐McKee, K., Udeh‐Momoh, C. T., Price, G. J., Bajaj, S., de Jager, C. A., Scott, D., Hadjichrysanthou, C., McNaughton, E., Bracoud, L., Ahmadi‐Abhari, S., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.010 · Cited by 28
Panayiotou, E., Fella, E., Andreou, S., Papacharalambous, R., Gerasimou, P., Costeas, P., Angeli, S., Kousiappa, I., Papacostas, S., & Kyriakides, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225417 · Cited by 30
Fish oil protects the blood–brain barrier integrity in a mouse model of Alzheimer’s disease
Xie, Y., Yan, L., Zeng, H., Chen, W., Lu, J., Wan, J., Su, H., & Yao, X. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00314-0 · Cited by 26
Glutamate Metabolism in Mitochondria is Closely Related to Alzheimer’s Disease
Song, J., Yang, X., Zhang, M., Wang, C., & Chen, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210595 · Cited by 26
“However, in a recent double-blind, placebo-controlled Phase III trial, its effectiveness at preventing cognitive decline in patients with mild AD was not significant [237].”
Aducanumab: A new hope in Alzheimer's disease
Ali, R., Gupta, G. D., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100039 · Cited by 37
Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
Jin, M., Wang, S., Gao, X., Zou, Z., Hirotsune, S., & Sun, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382231 · Cited by 28
“After some failures in clinical trials, such as those of bapineuzumab, solanezumab, and crenezumab (Salloway et al., 2014; Cummings et al., 2018; Honig et al., 2018), some monoclonal antibodies are now making it through to the late phase of clinical development.”
MethodNeuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 31
Tang, R.-H., & Liu, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00083 · Cited by 31
“Meanwhile, the failures of all phase III clinical trials targeting protein-modified drugs for AD may suggest the fact that the enrolled participants are really too advanced to obtain clinical benefit (Egan et al., 2018; Honig et al., 2018).”
BackgroundCNS critical periods: implications for dystonia and other neurodevelopmental disorders
Li, J., Kim, S., Pappas, S. S., & Dauer, W. T. (2021) · JCI Insight · doi:10.1172/jci.insight.142483 · Cited by 31
Beaurain, M., Salabert, A., Ribeiro, M. J., Arlicot, N., Damier, P., Jeune, F. L., Démonet, J., & Payoux, P. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00268 · Cited by 26
“Soon after this discovery, another study was therefore conducted to study the effect of this class of medication in patients with few or no symptoms (MMSE 20– 26) but positive amyloid PET imaging (109).”
BackgroundEffects of Combined Aerobic Exercise and Cognitive Training on Verbal Fluency in Older Adults
Nocera, J. R., Mammino, K., Kommula, Y., Wharton, W., Crosson, B., & McGregor, K. (2020) · Gerontology and Geriatric Medicine · doi:10.1177/2333721419896884 · Cited by 28
Chiang, T.-I., Yu, Y., Lin, C., & Lane, H. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.423 · Cited by 27
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 31
“However, the drug failed to improve cognitive function significantly in mild AD [208].”
Shen, Z. J., Fu, Y. B., Hou, J. L., Lin, L. N., Wang, X. Y., Li, C., & Yang, Y. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00698-1 · Cited by 28
“Moreover, almost all drugs targeting a single target or single process, such as solanezumab, bapineuzumab and aducanumab, have not shown significant efficacy [24, 25].”
Siemers, E., Hitchcock, J., Sundell, K. L., Dean, R. A., Jerecic, J., Cline, E. N., Iverson, K., Moore, J. A., Edgar, C. J., Manber, R., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.93 · Cited by 33
“Statistically significant differences or trends favoring treatment have been shown in clinical outcomes for antibodies targeting amyloid plaques [aducanumab (2) and donanemab (3)], soluble protofibrils [lecanemab (5)] and Aβ monomers [solanezumab (36)].”
BackgroundSelf-citationTargeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?
Tsitokana, M. E., Lafon, P., Prézeau, L., Pin, J., & Rondard, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032632 · Cited by 26
“infusion of 400 mg once a month for 80 weeks No reduced cognitive decline in mild AD patients versus placebo [73]”
BackgroundTrends in Alzheimer's Disease Research Based upon Machine Learning Analysis of PubMed Abstracts
Guan, R., Wen, X., Liang, Y., Xu, D. Y., He, B., & Feng, X. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35743 · Cited by 26
“But the results were disappointed as in the failure of the antibody, solanezumab, which held the promise of improving cognition but failed trial tests [20].”
ResultCao, K., Dong, Y., Xiang, J., Xu, Y., Li, Y., Song, H., Yu, W., Qi, X., & Guan, Z.-Z. (2019) · Aging · doi:10.18632/aging.102713 · Cited by 27
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 31
“Future trials with different doses andtimingofsolanezumabmayrequirefurtherexam-ination[99].”
Herline, K., Prelli, F., Mehta, P. D., MacMurray, C., Goñi, F., & Wısnıewskı, T. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0384-9 · Cited by 25
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 25
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 25
“Phase 3 clinical trials (NCT01900665) revealed that solanezumab, a monoclonal antibody against Aβ, showed no significant benefit with respect to preventing cognitive decline in patients with mild AD [97]; this failure suggests that earlier treatment may be critical for cognitive benefits.”
BackgroundInvasive and non-invasive therapies for Alzheimer’s disease and other amyloidosis
Pandey, G., & Ramakrishnan, V. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00752-y · Cited by 31
He, H., Liu, A., Zhang, W., Yang, H., Zhang, M., Xu, H. J., Liu, Y., Hong, B., Feng, Y., Yue, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210307 · Cited by 25
“However,allhigh-profiledrugstargetingA (cid:2) peptides or deposited amyloid plaques have failed [5–7].”
Petersen, K. K., Lipton, R. B., Grober, E. H., Davatzikos, C. A., Sperling, R. A., & Ezzati, A. (2022) · Neurology · doi:10.1212/wnl.0000000000200553 · Cited by 28
“Early diagnosis and intervention to reduce Aβ accumulation is considered a potential approach to modify disease course and has been the focus of many of the recent clinical trials involving cognitively normal (CN) participants.(3,4) Most of these trials require biomarker confirmation of amyloid positivity as a criteri…”
BackgroundAbelein, A., & Johansson, J. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00040k · Cited by 28
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 30
Grasping at straws: the failure of solanezumab to modify mild Alzheimer’s disease
Doggrell, S. A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1543397 · Cited by 25
“N Engl J Med 2018;378:321–30 [1] There is no cure for Alzheimer’s disease; the sixth leading cause of death in the USA, the leading cause of disability and poor health, takes a huge emotional and financial burden on family caregivers, and is costly to the state [2].”
BackgroundInfluentialPei, X., Lai, S., He, X., Masembe, N. P., Yuan, H., Yong, Z., Zhu, B. L., Wu, J., & Zhao, W. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s178854 · Cited by 25
Abdullah, L. I., Crawford, F., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Ait‐Ghezala, G., Paris, D., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00149 · Cited by 26
“These findings are also consistent with the results of several other experimental AD treatments where only very early stage AD subjects demonstrated benefit, such as Solanezumab (7, 10, 30), aducanumab (8), and LipiDiDiet trials (9).”
ResultChandupatla, R., Flatley, A., Feederle, R., Mandelkow, E., & Kaniyappan, S. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12097 · Cited by 29
“Some of these antibodies showed co-localization (yellow) with lysosomes (images 3, 6).”
Vukmir, R. B. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52042 · Cited by 28
Biomarker treatment effects in two phase 3 trials of gantenerumab
Bittner, T., Tonietto, M., Klein, G., Belusov, A., Illiano, V. P., Voyle, N., Delmar, P., Scelsi, M. A., Gobbi, S., Silvestri, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14414 · Cited by 25
“At 5).”
Wang, G., Kennedy, R., Goldberg, T. E., Fowler, M. E., Cutter, G., & Schneider, L. S. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228064 · Cited by 27
“Similar to previous trials [1, 3], we first estimated the mean (SD) of the 2-year change from baseline, then under the assumption of equal variance among the treatment groups, we estimate the sample size for a given treatment effect using two-sample t-tests and equal randomization ratio.”
BackgroundMethodInfluentialLu, J., Guo, P., Liu, X., Zhang, Y., Guo, X., Gao, X. Y., & Chen, Y. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/8302950 · Cited by 29
Liu, S., Lu, Y., Cai, X., Cong, R., Li, J., Jiang, H., & Li, M. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191023110712 · Cited by 25
Does Diet Have a Role in the Treatment of Alzheimer's Disease?
Thelen, M., & Brown‐Borg, H. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.617071 · Cited by 25
“Monoclonal antibodies designed to target and remove abnormal amyloid beta have shown no improvement in cognitive function in early and late stage AD patients (Doody et al., 2014; Salloway et al., 2014; Honig et al., 2018).”
BackgroundSingh, S. R., & Robbins, J. (2018) · Circulation Research · doi:10.1161/circresaha.118.312965 · Cited by 24
“The amyloid and protein aggregate field is littered with disappointments in large clinical trials when the supposed toxic entities are targeted.(17) Furthermore, it is of great interest to evaluate if monophosphorylated and cleaved desmin can seed PAO formation in other cardiomyopathies and thus represent a general pa…”
BackgroundGüell‐Bosch, J., Lope‐Piedrafita, S., Esquerda‐Canals, G., Montoliu‐Gaya, L., & Villegas, S. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4263 · Cited by 21
Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
Beshir, S. A., Hussain, N., Menon, V. B., Haddad, A. H. I. A., Zeer, R. A. K. A., & Elnour, A. A. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/2052142 · Cited by 44
Serum neurofilament light chain as a preclinical marker of neurodegeneration
Parnetti, L., Gaetani, L., & Filippo, M. D. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30405-3 · Cited by 21
Deep Brain Stimulation in Alzheimer’s Disease: Targeting the Nucleus Basalis of Meynert
Chen, Y., Shu, K., & Kang, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201141 · Cited by 25
Limiting RyR2 open time prevents Alzheimer's disease‐related deficits in the 3xTG‐AD mouse model
Liu, Y., Yao, J., Song, Z., Guo, W., Sun, B., Wei, J., Estillore, J. P., Back, T. G., & Chen, S. R. W. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24936 · Cited by 25
“Unfortunately, the effectiveness of this Aβ- targeted AD treatment strategy has yet to be demonstrated (Chakroborty et al., 2009; Honig et al., 2018; Karran et al., 2011).”
BackgroundGiampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 25
Recent Advances in Nanocrystals Heralding Greater Potential in Brain Delivery
Mule, S. R., Khairnar, P., & Shukla, R. (2022) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202200087 · Cited by 23
Mumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 24
Chen, C. D., McCullough, A. A., Gordon, B. A., Joseph‐Mathurin, N., Flores, S. E., McKay, N. S., Hobbs, D. A., Hornbeck, R. C., Fagan, A. M., Cruchaga, C., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06209-0 · Cited by 25
“11C-PiB has been used in prior trials of bapineuzumab [2] and ponezumab [3], and 18F-florbetapir has been used in prior trials of aducanumab [4], crenezumab [2], donanemab [5], gantenerumab [6], lecanemab [7], and solanezumab [8] (Table 1).”
MethodSelf-citationEsquer, A., Blanc, F., & Collongues, N. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00541-1 · Cited by 27
“A majority of patients were APOE4-positive, with nearly 60% in EXPEDI-TION and EXPEDITION 2 and 70% in EXPEDI-TION 3 [22, 23].”
BackgroundAnti-amyloid Antibody Therapies for Alzheimer’s Disease
Park, K. W. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00848-3 · Cited by 26
“Solanezumab binds a linear epitope in the middle domain (residues 16–26) of the Aβ molecule, which is buried in oligomers and fibrils, and therefore only targets soluble monomeric Aβ [26, 27].”
Chen, H., Perng, W., Chiou, J., Wang, Y., Huang, J., & Wei, J. C.-C. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.06.007 · Cited by 22
Cummings, J. L., Atri, A., Ballard, C. G., Boneva, N., Frölich, L., Molinuevo, J. L., Rakêt, L. L., & Tariot, P. N. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0443-2 · Cited by 22
Bartling, C. R. O., Jensen, T. M. T., Henry, S. M., Colliander, A. L., Sereikaité, V., Wenzler, M., Jain, P., Maric, H. M., Harpsøe, K., Pedersen, S. W., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10696 · Cited by 24
Alves, I. L., Heeman, F., Collij, L. E., Salvadó, G., Tolboom, N., Vilor‐Tejedor, N., Markiewicz, P. J., Yaqub, M. M., Cash, D. M., Mormino, E. C., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00819-2 · Cited by 24
Keret, O., Staffaroni, A. M., Ringman, J. M., Cobigo, Y., Goh, S. M., Wolf, A. A., Allen, I. E., Salloway, S., Chhatwal, J. P., Brickman, A. M., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12197 · Cited by 25
“Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 13(1), e12197.”
Chopra, G., Shabir, S., Yousuf, S., Kauts, S., Bhat, S. A., Mir, A. H., & Singh, M. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03042-8 · Cited by 25
“10 Solaneuzumab Mid domain of Aβ Passive immunization Clinical (phase III) (discontinued) • Could not improve cognitive decline [27, 157]”
BackgroundA Review of the Pathogenesis and Chinese Medicine Intervention of Alzheimer's Disease
Zhao, J., Yang, J., Li, D., Wang, F., & Li, L. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2201002 · Cited by 24
“For example, when A β acts on neurons, it can induce massive apoptosis through various cell signaling pathways [ 19,20].”
Evans, C. D., Sparks, J., Andersen, S. W., Brooks, D. A., Hauck, P. M., Mintun, M. A., & Sims, J. R. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13128 · Cited by 26
“16 Thus, the possibility of ARIA-E having a large impact on the results is unlikely.”
BackgroundSelf-citationAlzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 30
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 24
Lian, Y., Jia, Y., Wong, J., Zhou, X., Song, W., Guo, J., Masters, C. L., & Wang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02324-4 · Cited by 25
“Of these, solanezumab and crenezumab target the hydrophobic region in the middle of the A β peptide and bind speci fi cally to A β monomers, and have been found to have little effect on global A β -PET levels or cognitive decline despite reducing the level of free A β in cerebrospinal fl uid [40, 53].”
collaborators, F. T. I.-E., Vermunt, L., Terrera, G. M., ter Meulen, L., Veal, C., Blennow, K., Campbell, A., Carrié, I., Delrieu, J., Fauria, K., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0576-y · Cited by 21
Wang, S., Leem, J. S., Podvin, S., HOOK, V. Y. H., Kleschevnikov, N., Savchenko, P., Dhanani, M., Zhou, K., Kelly, I., Zhang, T., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.021 · Cited by 24
Quality of life of nursing home residents in mainland China: The role of children and family support
Xu, D., Mou, H., Gao, J., Zhu, S., Wang, X., Ling, J., & Wang, K. (2019) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2019.04.009 · Cited by 22
Research Attitudes Questionnaire scores predict Alzheimer’s disease clinical trial dropout
Stites, S. D., Turner, R. S., Gill, J., Gurian, A., Karlawish, J. H., Grill, J. D., & Study, F. T. A. D. C. (2021) · Clinical Trials · doi:10.1177/1740774520982315 · Cited by 26
Genetic Therapies for Alzheimer’s Disease: A Scoping Review
Lennon, M. J., Rigney, G., Raymont, V., & Sachdev, P. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215145 · Cited by 26
“…using passive [5] and active [6] immunization against amyloid and tau targets have been shown to engage the target in the brain but have largely failed to show cognitive ) [19]. benefit (e.g., solanezumab [7], gantenerumab [8], bapineuzumab [9], gosuranemab [10], semorinemab [11], and CAD106 [12]).”
Chen, Y., Therriault, J., Luo, J., Ba, M., Zhang, H., & Initiative, A. D. N. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2004088 · Cited by 21
Tang, M.-Y., Gorin, F. A., & Lein, P. J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.05 · Cited by 25
“However, therapeutic strategies for decreasing Aβ plaque load[5,6], reducing Aβ production with BACE-1 inhibitors[7], or inhibiting hyperphosphorylated tau aggregation[8], have been largely unsuccessful in clinical trials over the past several years[3].”
BackgroundWang, G., Liu, L., Li, Y., Aschenbrenner, A. J., Bateman, R. J., Delmar, P., Schneider, L. S. S., Kennedy, R., Cutter, G., & Xiong, C. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12286 · Cited by 23
Ramakrishnan, V., Friedrich, C. M., Witt, C. M., Sheehan, R., Pryor, M. M., Atwal, J. K., Wildsmith, K. R., Kudrycki, K., Lee, S., Mazer, N. A., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12876 · Cited by 23
Punyakoti, P., Behl, T., Sehgal, A., Yadav, S., Sachdeva, M., Anwer, M. K., Vargas-De-La-Cruz, C. B., Venkatachalam, T., Naqvi, M., Verma, R., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110539 · Cited by 20
The Gut Microbiome and Alzheimer’s Disease: A Growing Relationship
Zerdan, M. B., Hebbo, E., Hijazi, A., Gemayel, M. E., Nasr, J., Nasr, D., Yaghi, M., Bouferraa, Y., & Nagarajan, A. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221227090125 · Cited by 24
Chhabra, A., Solanki, S., Saravanabawan, P., Venkiteswaran, A., Nimmathota, N., & Modi, N. M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2416947 · Cited by 26
“In the solanezumab studies, the CDR-SB score changed from baseline by 2.21 [20], 0.1, 1.69(0.13) [21], and 2 [22] respectively.”
InfluentialZhang, D., Lu, X., He, S., Li, W., Ao, R., Leung, F. C.-Y., Zhang, Z., Chen, Q., & Zhang, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15006 · Cited by 19
Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data
Nader, C. A., Ayache, N., Frisoni, G. B., Robert, P. H., Lorenzi, M., & Initiative, A. D. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab091 · Cited by 24
“Although the amyloid hypothesis has been recently invi-gorated by a post-hoc analysis of the aducanumab trial, 10 clinical trials failed so far to show efficacy of this kind of treatments, 11 as the clinical primary endpoints were not met, 12–14 or because of unacceptable adverse effects.”
MethodSetbacks in Alzheimer research demand new strategies, not surrender
Jobke, B., McBride, T. C., Nevin, L. M., Peiperl, L., Ross, A. J., Stone, C., Turner, R. C., & Editors, A. T. P. M. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002518 · Cited by 20
Multitarget-directed Ligands for Neurodegenerative Diseases: Real Opportunity Or Blurry mirage?
Benchekroun, M., & Maramai, S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0249 · Cited by 21
Holdridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13031 · Cited by 19
“14 Therefore, the aim of this meta-analysis was to estimate the effect of low-dose solanezumab treatment versus placebo on cognitive and functional scales in the AD with mild dementia population across all three EXPEDITION studies, as well as to estimate the posterior probability that solanezumab…”
Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease
Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025) · Brain Sciences · doi:10.3390/brainsci15101101 · Cited by 22
A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
Cury, R. D. M., da Silva, T., Cezar‐dos‐Santos, F., Fakih, Y. R. C., Narvaez, K. A. R., Gouvea, M. C., Espínola, C., Ferreira, C. F., de Castro, W. A. C., Pamplona, F. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389608 · Cited by 25
Aggregation Mechanism of Alzheimer’s Amyloid β-Peptide Mediated by α-Strand/α-Sheet Structure
Balupuri, A., Choi, K.-E., & Kang, N. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031094 · Cited by 23
“gov identifier: NCT01900665) [12] and Gantenerumab (Funded by Roche; ClinicalTrials.”
BackgroundInfluentialAquino, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694329 · Cited by 24
Zhu, H., Mehta, M., Huang, S. M., & Wang, Y. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2536 · Cited by 20
The Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 24
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha, N., Wali, Z., Pinky, P., Hattiwale, S. H., Jamal, A., & Parvez, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102134 · Cited by 20
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19
“However, it is plausible a limited clinical relevance of these effects detected with neuropsychological questionnaires, as showed by the EXPEDITION3 study [40].”
BackgroundZeng, B., Tang, C., Wang, J., Yang, Q., Ren, Q., & Liu, X. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240161 · Cited by 25
Fang, G., Shi, B., Wu, K., Chen, S., Gao, X., Xiao, S., Kang, J. X., Li, W., & Huang, R. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1533824 · Cited by 21
Yagi, T., Kanekiyo, M., Ito, J., Ihara, R., Suzuki, K., Iwata, A., Iwatsubo, T., Aoshima, K., Initiative, A. D. N., & Initiative, J. A. D. N. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.004 · Cited by 20
“However, some disease-modifying therapeutics have failed to provide statistically significant clinical benefit in the early stage of AD who had biomarker evidence of brain Ab deposition [7].”
BackgroundIs anti-ageing drug discovery becoming a reality?
Moskalev, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1702965 · Cited by 19
“have not shown cognitive improvement [21,22].”
Wu, Y., Yang, L., Jiang, W., Zhang, X., & Yao, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00190 · Cited by 23
Li, X., Wang, L., Cykowski, M. D., He, T., Liu, T., Chakranarayan, J., Rivera, A. L., Zhao, H., Powell, S. Z.-E., Xia, W., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.030 · Cited by 20
“[26] Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, et al.”
BackgroundIdentification and analysis of a selective DYRK1A inhibitor
Lin, T. E., Chao, M., HuangFu, W., Tu, H., Peng, Z., SU, C., Sung, T.-Y., Hsieh, J., Lee, C., Yang, C., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112580 · Cited by 19
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.